Evidence map›Paper›PMID 42582406›Full record

ArticleAnnals of surgical treatment and research2026

Comparison of postoperative survival after neoadjuvant treatment

Wonjun Jang, Hye-Sol Jung, Youngmin Han, Yoonsoo Chae, Younsoo Seo, Inhyuck Lee, Young Jae Cho, Go-Won Choi, Joon Seong Park, Jin-Young Jang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wonjun JangDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0001-8484-4934
Hye-Sol JungDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2041-4214
Youngmin HanDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0456-7824
Yoonsoo ChaeDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-2762-3286
Younsoo SeoDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0009-2096-6121
Inhyuck LeeDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-9261-7777
Young Jae ChoDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-2255-8390
Go-Won ChoiDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0001-7815-9834
Joon Seong ParkDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-8048-9990
Jin-Young JangDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3312-0503
Wooil KwonDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-4827-7805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Evidence regarding long-term prognosis after surgery by pathological stage in pancreatic ductal adenocarcinoma (PDAC) patients following neoadjuvant treatment (NAT) remains limited. Methods: 757 patients who underwent PDAC resection between 2017 and 2021 were analyzed retrospectively. Among them, 262 received NAT followed by surgery (NAT group) and 415 underwent upfront surgery (UFS group). Propensity score matching (PSM) was performed for balanced comparison using the following variables: age, sex, American Society of Anesthesiologists physical status class, and adjuvant treatment. Results: After PSM, the UFS group showed higher postoperative CA 19-9, larger tumors, less advanced initial clinical stage, but more advanced pathological stage and fewer positive lymph nodes compared with the NAT group. Median overall survival (OS) was similar between groups (NAT Conclusion: Postoperative survival did not differ between NAT and UFS groups when stratified by pathological stage, except for stage IA where UFS showed better outcomes.

Indexed as

Neoadjuvant therapyNeoplasm stagingPancreatic neoplasmsPrognosisSurvival

Identifiers

PMID42582406
PMCPMC13457791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.